Amgen is investing in Fortuna Fix, a Canadian stem cell company, according to Endpoints News.
Here are five insights:
1. Amgen is leading the $25 million financing round.
2. The startup, Fortuna Fix, is striving to develop novel techniques for re-growing damaged neural tissue.
3. Fortuna Fix has re-engineered multipotent stem cells into neural stem cells.
4. The idea is providers can inject these cells into patients multiple times, creating a treatment processes for tissue regeneration.
5. This investment reflects Amgen's first in the regenerative medicine space.